Evidence map›Paper›PMID 40902212›Full record

ArticleSeminars in arthritis and rheumatism2025

Item selection for the development and validation of a revised classification criteria for adult and juvenile idiopathic inflammatory myopathies: MyoROC project.

Didem Saygin, Rachel Zeng, Stefanie Glaubitz, Matteo Bottai, Anthony A Amato, Lorenzo Cavagna, Sonye K Danoff, Marianne de Visser, Mazen M Dimachkie, Manabu Fujimoto and 14 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Seminars in arthritis and rheumatism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Didem SayginDivision of Rheumatology, Department of Medicine, Rush University Medical Center, Chicago, IL, USA.
Rachel ZengDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany; Department of Neurology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Stefanie GlaubitzDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Matteo BottaiDivision of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Anthony A AmatoDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lorenzo CavagnaDepartment of Internal Medicine and Therapeutics, University of Pavia, Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Sonye K DanoffDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Marianne de VisserDepartment of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Mazen M DimachkieDepartment of Neurology, The University of Kansas Medical Center, Kansas City, KS, USA.
Manabu FujimotoDepartment of Dermatology, Osaka University, Osaka, Japan.
Masataka KuwanaDepartment of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
Pedro M MachadoDepartment of Neuromuscular Diseases, University College London, London, UK; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK; NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Merrilee NeedhamDepartment of Neurology Fiona Stanley Hospital, University of Notre Dame, Murdoch University and the Perron Institute, Perth, Western Australia, Australia.
Clarissa PilkingtonGreat Ormond Street Hospital, London, UK.
Liza RajasekharDepartment of Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
Lisa G RiderEnvironmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA.
Yasser SalemPhysical Therapy Program, Hofstra University Hempstead, NY, USA.
Samuel Katsuyuki ShinjoDivision of Rheumatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil.
Jasvinder A SinghMedicine Service, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; Department of Medicine at the School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL 35233, USA.
Mohammed TiklyDivision of Rheumatology, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Guochun WangDepartment of Rheumatology, Key Myositis Laboratories, China-Japan Friendship Hospital, Beijing, China.
Victoria P WerthDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine and CMCVAMC, Philadelphia, PA, USA.
Rohit AggarwalDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Ingrid E LundbergDivision of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden. Electronic address: ingrid.lundberg@ki.se.

Funding

Assessment, Therapy and Prevention Of Autoimmune DiseaseZIAES101081 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$17.6M
The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SINGH, JASVINDER A · 2012 to 2021
$12.8M
Genetics of Osteoarthritis Susceptibility, Heterogeneity and ProgressionR01AR082839 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Merry-Lynn Noelle McDonald Donnelly · 2024 to 2026
$1.9M
Intramural NIH HHS ZIA ES101081NIAMS NIH HHS P50 AR060772NIAMS NIH HHS R01 AR082839
6 · The paper itself

Abstract

objectiveA revision of the 2017 EULAR-ACR myositis classification criteria, namely EULAR-ACR funded Myositis Revision of Classification (MyoROC) project, is currently underway involving a large international group of experts. In the first phase of this project, we identified additional items to be tested in the criteria.

methodsWe distributed an electronic survey to International Myositis Assessment and Clinical Studies (IMACS) members to identify new items. The identified items were discussed within the Steering Committee and a multi-step Delphi consensus process consisting of an open discussion and three rounds of e-voting were conducted to reach the final item list.

resultsThe IMACS survey results revealed 24 new items. After an open discussion with Steering Committee members, 14 items were dropped and five new items were added, resulting in a total of 15 items. After three rounds of e-voting, the following variables were agreed to be tested in addition to the original items: finger flexion, knee extension ≥ hip flexion weakness, myonecrosis pattern on biopsy, magnetic resonance imaging and electromyography findings of myositis, additional rashes, skin biopsy, capillaroscopy, interstitial lung disease, arthritis, Raynaud's phenomenon, myositis-specific (MSA) and -associated autoantibodies, enzyme elevation at ≥2 time points, and aldolase.

conclusionThe new items that will be tested in the revised criteria were generated with input from a wide range of stakeholders and included, most importantly, MSA, pattern of weakness, skin changes, and additional diagnostic modalities. The next steps of the project are data collection followed by statistical analysis for development and validation of the revised criteria.

Indexed as

MyositisAdultChildConsensusDelphi TechniqueHumansSurveys and QuestionnairesAnti-synthetase syndromeClassificationMyopathyMyositis

Identifiers

PMID40902212
PMCPMC12619961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.